Quantcast

Latest BioDelivery Sciences International Inc. Stories

2014-10-10 12:24:40

RALEIGH, N.C., Oct. 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that J. Chris Prue, RPh, MBA has joined BDSI as Vice President of Regulatory Affairs and Quality Assurance. Mr. Prue brings more than 30 years of pharmaceutical industry experience in regulatory affairs and quality assurance to BDSI. He has held positions of increasing responsibility at The Upjohn Company, Glaxo Inc., GlaxoWellcome and Purdue Pharma LP. Recently...

2014-10-06 20:23:33

Conference Call Scheduled for Tuesday, October 7 at 8:00 AM Eastern Time RALEIGH, N.C., Oct. 6, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) will host an investor update conference call and webcast to discuss the launch of BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) which has been approved by the U.S. Food and Drug Administration (FDA) for the maintenance treatment of opioid dependence. The conference call and webcast will...

2014-09-08 08:29:15

RALEIGH, N.C., Sept. 8, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Morgan Stanley Global Healthcare Conference. The presentation is scheduled for Tuesday, September 9, 2014 at 4:40 p.m. Eastern Time at the Grand Hyatt in New York City. The presentation will be webcast live and can be accessed at www.bdsi.com. For those who are not available to...

2014-09-03 08:32:49

September 4th ceremony celebrates 2014 accomplishments including FDA approval and anticipated commercial launch of BUNAVAIL RALEIGH, N.C., Sept. 3, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the company will visit the NASDAQ MarketSite in Times Square on September 4, 2014. In honor of the occasion, Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will ring the opening bell for the trading session that day....

2014-08-27 08:27:45

RALEIGH, N.C., Aug. 27, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the company will be hosting an investor and analyst event and simultaneous webcast on Friday, September 5, 2014. The event is scheduled for 12-2 pm ET in New York City. http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO At this event, BDSI senior management will discuss the commercialization and launch plan for BUNAVAIL and provide updates on the BEMA(®)...

2014-08-12 08:29:19

BEMA Buprenorphine on track for late 2014 or early 2015 NDA filing by partner Endo Pharmaceuticals RALEIGH, N.C., Aug. 12, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that along with its commercial partner, Endo Pharmaceuticals, engaged in a positive pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding BEMA Buprenorphine for the management of pain severe enough to require daily, around-the-clock,...

2014-08-07 16:29:42

BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) approved by FDA for the maintenance treatment of opioid dependence; US launch planned for late Q3 RALEIGH, N.C., Aug. 7, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 with the U.S. Securities and Exchange Commission and, in connection therewith, is providing a review of BDSI's recent achievements and an...

2014-08-06 08:30:30

RALEIGH, N.C., Aug. 6, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that it has completed a pre-specified interim analysis of the ongoing initial pivotal Phase 3 trial for Clonidine Topical Gel for the treatment of painful diabetic neuropathy (PDN). http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO The interim analysis was performed on data from the first 50% of patients who completed the study. The purpose of the interim...

2014-07-22 08:31:15

RALEIGH, N.C., July 22, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that its Board of Directors has appointed Charles J. (Chuck) Bramlage and Dr. Barry I. Feinberg as members of the Board. http://photos.prnewswire.com/prnvar/20110217/CL49801LOGO Mr. Bramlage is a veteran pharmaceutical industry executive with extensive experience in marketing, sales and other commercial functions. He is currently the Chief Executive Officer of...

2014-07-07 08:27:32

- Pre-NDA meeting scheduled with FDA in July DUBLIN and RALEIGH, N.C., July 7, 2014 /PRNewswire/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today positive top-line results from its pivotal Phase III efficacy study of BEMA buprenorphine in opioid-experienced patients. BEMA buprenorphine is being developed for the management of pain severe enough to require...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related